Aptar Pharma opens new R&D center in France
Expanded capabilities that continue to push the boundaries of innovation—advancing drug delivery solutions for patients, customers, and consumers around the world
Expanded capabilities that continue to push the boundaries of innovation—advancing drug delivery solutions for patients, customers, and consumers around the world
Amgen has invested over $40 billion in manufacturing and research and development in US since 2017
The collaboration is expected to facilitate access to world-class treatments and specialised care for Iraqi personnel
Air Liquide will provide care for people living with respiratory diseases such as chronic obstructive pulmonary disease (COPD) and sleep apnea
Hengrui is eligible to receive regulatory and commercial milestone payments of up to US$1.093 billion
Clinical evidence has consistently highlighted lacosamide’s efficacy and safety.
Keytruda Qlex is the first and only subcutaneously administered immune checkpoint inhibitor that can be given by a health care provider in as little as one minute
Pegozafermin offers a distinct mechanism of action with potential for enhanced efficacy and tolerability and opportunities for combination development with incretins
Funding supports development of first-in-class pan-ROCK inhibitor ROC-101 through Phase 2a clinical testing
Subscribe To Our Newsletter & Stay Updated